Why Are Brokerages Cautious on Aurobindo Pharma After the Lannett Deal?

By NDTV Profit

Community Score: 50% | 24 views | 2d

0 community ratings: null thumbs up, null thumbs down

Aurobindo Pharma is back in focus after global brokerages Citi and Macquarie turned cautious on the stock following the Lannett deal. While the brokerages flagged concerns around US sales, Lannett performance, biosimilar competition and rich valuations, company sources remain confident about the long-term growth story. With ₹10,000 crore of investments nearing monetization and businesses like respiratory, injectables, biosimilars and CDMO entering commercialization, can Aurobindo Pharma deliver its next phase of growth? Watch now! #aurobindo #pharma #brokerage #stockmarket #ndtvprofit For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia Visit NDTV Profit for more news: https://www.ndtvprofit.com/ Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports Follow NDTV Profit here Twitter: https://twitter.com/NDTVProfitIndia , https://twitter.com/NDTVProfit LinkedIn: https://www.linkedin.com/company

Tags: ndtv profit, stock market, stock market news, stock market india, stock market today, share market live, top stocks in focus, top stocks to buy, nifty live, union budget news, finance news, latest finance news, business news, latest business news, business news today, aurobindo pharma, lannet, aurobindo lannet, aurobindo share, aurobindo share price